Skip to content
10-Q

Quarterly Report

VIROPHARMA INC

0001104659-13-035885

← back to feed
Filed
May 1, 2013 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2013 · Apr 22, 2013 65.31M sh
Shares Diluted Q1 2013 · Mar 31, 2013 65.21M sh
Shares Diluted Q1 2013 · Mar 31, 2012 85.03M sh
Capex Q1 2013 · Mar 31, 2013 $857K
Capex Q1 2013 · Mar 31, 2012 $267K
Cash And Equivalents Q1 2013 · Mar 31, 2013 $199.2M
Cash And Equivalents Q1 2013 · Dec 31, 2012 $175.52M
Cash And Equivalents Q1 2013 · Mar 31, 2012 $363.65M
Cash And Equivalents Q1 2013 · Dec 31, 2011 $331.35M
Stockholders Equity Q1 2013 · Mar 31, 2013 $700.54M
Stockholders Equity Q1 2013 · Dec 31, 2012 $757.04M
Current Liabilities Q1 2013 · Mar 31, 2013 $100.66M
Current Liabilities Q1 2013 · Dec 31, 2012 $114.03M
Total Liabilities Q1 2013 · Mar 31, 2013 $407.38M
Total Liabilities Q1 2013 · Dec 31, 2012 $462.91M
Current Assets Q1 2013 · Mar 31, 2013 $456.83M
Current Assets Q1 2013 · Dec 31, 2012 $453.42M
Total Assets Q1 2013 · Mar 31, 2013 $1.11B
Total Assets Q1 2013 · Dec 31, 2012 $1.22B
Eps Diluted Q1 2013 · Mar 31, 2013 −$0.98
Eps Diluted Q1 2013 · Mar 31, 2012 $0.26
Eps Basic Q1 2013 · Mar 31, 2013 −$0.98
Eps Basic Q1 2013 · Mar 31, 2012 $0.28
Sga Expense Q1 2013 · Mar 31, 2013 $42.72M
Sga Expense Q1 2013 · Mar 31, 2012 $37.95M
Rd Expense Q1 2013 · Mar 31, 2013 $17.2M
Rd Expense Q1 2013 · Mar 31, 2012 $15.4M
Operating Income Q1 2013 · Mar 31, 2013 −$97.86M
Operating Income Q1 2013 · Mar 31, 2012 $40.31M
Cost Of Revenue Q1 2013 · Mar 31, 2013 $29.86M
Cost Of Revenue Q1 2013 · Mar 31, 2012 $32.08M
Stock Repurchased Q1 2013 · Mar 31, 2012 $50M